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Abstract
Background: Observational studies have reported an association between allergic 
disease and mental health, but a causal relationship has not been established. Here, 
we use Mendelian randomization (MR) to investigate a possible causal relationship 
between atopic disease and mental health phenotypes.
Methods: The observational relationship between allergic disease and mental health 
was investigated in UK Biobank. The direction of causality was investigated with bi-
directional two- sample MR using summary- level data from published genome- wide 
association studies. A genetic instrument was derived from associated variants for a 
broad allergic disease phenotype to test for causal relationships with various mental 
health outcomes. We also investigated whether these relationships were specific to 
atopic dermatitis (AD), asthma or hayfever. Given the multiple testing burden, we ap-
plied a Bonferroni correction to use an individual test p- value threshold of .0016 (32 
tests).
Results: We found strong evidence of an observational association between the 
broad allergic disease phenotype and depression (ORself- report=1.45, 95% CI: 1.41– 
1.50, p = 3.6 × 10−130), anxiety (OR=1.25, 95% CI: 1.18– 1.33, p = 6.5 × 10−13), bi-
polar disorder (ORself- report=1.29, 95% CI: 1.12– 1.47, p = 2.8 × 10
−4) and neuroticism 
(β = 0.38, 95% CI: 0.36– 0.41, p = 6.8 × 10−166). Similar associations were found be-
tween asthma, AD, hayfever individually with the mental health phenotypes, although 
the associations between AD and hayfever with bipolar disorder were weaker. There 
was little evidence of causality in either direction (all p- values>.02).
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2021 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
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1  |  INTRODUC TION
There is a well- documented relationship between allergic disease 
(including asthma, atopic dermatitis (AD) and hayfever) and mental 
health.1- 3 However, it is unclear whether this association is causal, 
or whether confounding factors, or reverse causality, could explain 
the observed association. Prevalence of common mental health dis-
orders and allergic disease is increasing.4 Common mental health 
disorders such as anxiety and depression are some of the largest 
contributors to the global burden of disease. Establishing whether 
there is a causal relationship is therefore important, as this could 
highlight whether effectively treating allergic disease would lead to 
a reduction in the burden of mental health issues (or vice versa).
Increased prevalence of disorders such as depression, anxiety, 
schizophrenia, conduct disorder and autism are observed among 
individuals with AD, particularly those most severely affected.5,6 
Other studies have found evidence of an association between asthma 
and hayfever with bipolar disorder, depression and schizophrenia.7,8 
Conclusion: Using MR, we were unable to replicate most of the phenotypic asso-
ciations between allergic disease and mental health. Any causal effects we detected 
were considerably attenuated compared with the phenotypic association. This sug-
gests that most comorbidity observed clinically is unlikely to be causal.
K E Y W O R D S























G R A P H I C A L  A B S T R A C T
We found strong evidence of an observational association between the broad allergic disease phenotype and depression, anxiety, bipolar 
disorder and neuroticism. Similar associations were found between asthma, AD, hayfever individually with the mental health phenotypes. 
When using Mendelian randomization to investigate causality, we found little evidence of causality in either direction. Mendelian 
randomization suggests observational associations between allergic disease phenotypes and mental health may be inflated
Key Messages
• Mendelian randomization suggests phenotypic associa-
tions between allergic disease and mental health may be 
inflated
• We did not find evidence of causal effects between al-
lergic disease genetic risk and mental health
• Phenotypic analyses were restricted to older adults so 
findings may not generalize to younger populations
is supported by a Norwegian Research 
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Several hypotheses have been suggested for a causal role of aller-
gic disease on mental health; these include both psychosocial and 
biological mechanisms. It is possible that social consequences of al-
lergic disease, such as embarrassment due to visible lesions or itch-
ing resulting from AD, or results of sleep deprivation are the driving 
force behind later mental health issues. An alternative hypothesis is 
the “inflammatory hypothesis,” which suggests that the effects of 
allergic disease on the immune system (such as disturbances in the 
inflammatory system or increased levels of inflammatory cytokines) 
could contribute to the presence of mental health disorders.9,10
If these associations reflect a true causal effect of allergic disease 
on mental health, this could suggest targets for potential intervention 
and prevention targets for subsequent mental health problems. For 
example, screening, monitoring and/or early intervention among al-
lergic disease patients could reduce the risk of later bipolar disorder. 
If the effects do act via inflammatory mechanisms, then repurposing 
existing treatments for inflammatory disease could be effective here. 
Nonsteroidal anti- inflammatory drugs (NSAIDS) have been suggested 
to be an effective adjunct therapy for bipolar disorder; however, this 
finding remains inconclusive.11,12 Studies investigating the progres-
sion of disease rather than onset will further inform on the effective-
ness of repurposing opportunities to treat current sufferers.13
We used data from the UK Biobank (UKB) study to investigate the 
phenotypic associations between allergic disease and mental health 
in a population of European ancestry. UKB is a large longitudinal co-
hort that recruited participants in the UK aged 40 years and above 
to investigate the contribution of genetics and environment to the 
development of disease. We also performed two- sample Mendelian 
randomization (MR) using summary data from relevant genome- 
wide association studies (GWAS) to investigate the causal nature of 
these associations. MR enables us to infer causality using observa-
tional data. The method uses genetic variants as a proxy for modifi-
able exposures, and subject to the instrumental variable assumptions 
holding, should not be subject to the issues affecting conventional 
observational epidemiology.14,15 This is based on the assumptions 
that the instrumental variable is truly associated with the exposure 
and not associated with confounders, and also has an effect upon the 
outcome via the exposure and not via alternative pathways.14
Disentangling the nature of the relationship between allergic dis-
ease and mental health could enable us to focus efforts on improv-
ing intervention or prevention strategies. Whether there is a causal 
effect of allergic disease on mental health, as suggested by previous 
observational studies, is a critical question for intervening on the 
initial presentation of allergic disease to improve mental health out-
comes of patients.
2  |  METHODS
2.1  |  Study populations
2.1.1  |  Phenotypic association— UK Biobank
Data were available from UKB for individuals aged between 37 
and 73 years,16 including those with asthma, AD, hayfever and the 
broad allergic disease phenotype (any one of asthma, AD or hayfe-
ver) (Table 1). Phenotype data were also available for mental health 
and personality traits including depression, anxiety, bipolar disorder, 
schizophrenia and neuroticism. All individuals were of European eth-
nicity who had provided written informed consent. UKB is approved 
by the National Health Service National Research Ethics Service (ref 
11/NW/0382; UKB application number 9142).
Mental health and personality phenotypes
Self- reported measures of depression, anxiety, bipolar disorder and 
schizophrenia were derived from responses to the verbal interview 
conducted at the initial assessment centre. Responses to this inter-
view are recorded in the non- cancer illness item (variable 20002; cat-
egories: depression = 1286, anxiety = 1287, bipolar disorder = 1291, 
schizophrenia = 1289). We also included stricter definitions of major 
depressive disorder (MDD) and bipolar disorder that were derived 
from responses to the touchscreen questionnaire at recruitment 
(variable: 20126). Neuroticism summary scores were based on 12 
neurotic behaviour domains (variable:20127). The neuroticism scores 
and stricter MDD and bipolar definitions were originally derived by 
Smith et al17; full details are included in the Appendix S1.
Allergic disease phenotypes
Asthma, AD and hayfever phenotypes were also derived from the 
non- cancer illness item collected at the first assessment centre 
via verbal interview (variable 20002; categories: asthma = 1111, 
AD = 1452, hayfever = 1387). Participants were designated as 
controls for the relevant phenotype if they did not report asthma, 
AD or hayfever based on the non- cancer illness item, and if they 
did not report a doctor diagnosis of asthma or AD/hayfever as part 
of the touchscreen questionnaire (variable: 6152). When screen-
ing the controls for AD and hayfever, it was not possible to tease 
these disorders apart using the touchscreen questionnaire so in-
dividuals answering yes to this question were excluded from both 
the AD and hayfever controls. A broad allergic disease phenotype 
was derived from these phenotypes, participants reporting either 
asthma, hayfever or AD (or any combination of these phenotypes) 
Trait Cases / controls (prevalence) N
Allergic disease (broad phenotype) 78,768/369,866 (17.6%) 448,634
Asthma 53,031/398,301 (11.8%) 451,332
Atopic Dermatitis 11,571/441,038 (2.6%) 452,609
Hayfever 25,471/427,220 (5.6%) 452,691
TA B L E  1  Descriptive statistics of UK 
Biobank individuals with allergic disease
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were assigned case status. Participants who did not report either 
asthma, AD or hayfever as described for the individual phenotypes 
were designated as controls.
2.1.2  |  Causal relationship— Summary GWAS data
Published summary GWAS results were available for the most re-
cent GWAS for the broad allergic disease phenotype (n = 360,868), 
which had considered the existence of any one of the atopic 
triad (asthma, AD and hayfever)18 and identified 89 independent 
(r2 < 0.01) single nucleotide polymorphisms (SNPs) at p < 5 × 10−8. 
Summary GWAS results were also available for recent large 
scale GWAS of each of the atopic triad individually, and we used 
these to identify specific genetic instruments. Independent SNPs 
(r2 < 0.01) associated at the genome- wide significance threshold 
were identified for asthma (n = 127,669; 16 SNPs),19 hayfever 
(n = 38,838; 37 SNPs)20 and AD (n = 40,835; 23 SNPs)21 (Tables 
S1- S4, S10). Effect sizes for each of these SNPs were extracted 
from recent GWAS of each mental health phenotype to create our 
outcome datasets.
Similarly, published GWAS results were available for the men-
tal health outcomes investigated; MDD,22 bipolar disorder,23 
schizophrenia,24 neuroticism25 and anxiety.26 Genetic instruments 
were derived from associated independent variants (p < 5 × 10−8; 
r2 < 0.01) reported for MDD (32 SNPs),22 bipolar disorder (22 
SNPs),23 anxiety (5 SNPs),27 schizophrenia (79 SNPs)24 and neuroti-
cism (66 SNPs)25 (Tables S5- S9, S10). All published results were from 
analyses restricted to individuals of European ancestry.
2.2  |  Statistical analyses
An overview of the analyses is shown in Figure S1. In brief, we 
looked at the phenotypic association between broad allergic dis-
ease, asthma, AD and hayfever with depression, MDD, anxiety, 
bipolar disorder, schizophrenia and neuroticism. Bidirectional MR 
analyses were performed between each of the allergic disease 
phenotypes and MDD, anxiety, bipolar disorder, schizophrenia and 
neuroticism.
2.2.1  |  Observational analyses
Observational analyses were carried out using individual level data 
from UKB participants to investigate the phenotypic association 
between the allergic disease phenotypes and psychiatric traits. 
This was performed using linear or logistic regression as appropri-
ate while adjusting for age and sex. All observational analyses were 
performed using Stata 15.28 Given the multi- testing burden, we 
note that a global p = .05 is equivalent to an individual test p- value 
of  .0016 (32 tests).
2.2.2  |  Analysis of causal relationships
MR was then performed using the TwoSample MR R package29 to 
determine the causal effect of allergic disease liability upon the risk 
for mental disorders (Figure 1a). A causal estimate was obtained 
using the multiplicative random- effects inverse- variance weighted 
(IVW) method, which is akin to a weighted regression of the SNP- 
outcome coefficients upon the SNP- exposure coefficients. In doing 
so, the SNP- exposure and SNP- outcome associations were com-
bined in a meta- analysis. For ease of interpretation, the resulting 
causal estimates were multiplied by 0.693 to represent the change 
in outcome per doubling odds of the exposure as demonstrated by 
Burgess and Labreque.30
MR analyses were also performed in the reverse direction to 
estimate the causal effect of liability for mental health traits upon 
allergic disease risk (Figure 1b).
2.2.3  |  Sample overlap
UKB participants were included in the discovery samples for the broad 
allergic disease phenotype, hayfever, MDD and anxiety. This sample 
overlap has the potential to bias causal effect estimates towards the 
phenotypic exposure- outcome association.31 To avoid sample overlap, 
we generated genetic instruments for MDD (Wray et al. 2018) based 
on summary statistics excluding UKB (31 SNPs). Summary data for 
hayfever excluding UKB were also available when hayfever was the 
outcome.20 An alternative anxiety genetic instrument was also gener-
ated using SNP- exposure coefficients from an older anxiety GWAS 
that did not include UKB.26 Due to limitations of data availability, there 
were some analyses where sample overlap could not be avoided, these 
being when investigating causality between the broad allergic disease 
and neuroticism (estimated sample overlap =42.0%) and for hayfever 
and neuroticism (estimated sample overlap =44.4%).
2.2.4  |  Sensitivity analyses
The causal estimate could be biased by SNPs within the genetic 
instrument which act through a horizontally pleiotropic pathway 
(whereby a SNP affects the outcome by a path other than via the 
exposure— the bottom dotted arrows in Figure 1). We used four 
sensitivity methods that rely on different assumptions to test for 
or account for potential pleiotropy. These are MR- Egger regres-
sion,32 weighted median analysis32 and the weighted mode- based 
estimate (MBE)33 and Cochran's Q statistic.34 The Steiger direc-
tionality test was also performed to ensure the variance explained 
by the genetic instrument was greater in the exposure compared 
with the outcome.35 Where we found evidence of a causal associa-
tion, we performed a look up of SNPs in the relevant instrument 
using PhenoScanner36,37 to identify any that could be associated 
with pleiotropic traits.
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All MR analyses were performed using R (www.r- proje ct.org). 
The code and datasets used to carry out the MR analyses are avail-
able on GitHub (https://github.com/abudu - aggre y/Aller gic_Disea 
se_Mental_Health_MR).
3  |  RESULTS
3.1  |  Observational analyses
We found strong observational evidence for an association of the 
broad allergic disease phenotype with both self- reported depression 
(OR=1.45; 95% CI: 1.41– 1.50; p- value = 3.63 × 10−130) and MDD 
(OR=1.40; 95% CI: 1.35– 1.46; p- value=2.63×10−76) (Figure 2a, 
Table S11). A strong association was also seen between depression 
and the individual asthma, AD and hayfever phenotypes, though 
with different magnitudes (Figure 2a, Table S11). However, we note 
that adult prevalence of AD (5%– 10%),38 asthma (18.2%)39 and hay-
fever (10%– 30%)40 in the population is greater than that identified 
in UKB (Table 1).
We also found evidence of an association between anxiety and 
the broad allergic disease phenotype (OR=1.25; 95% CI: 1.18– 1.33; 
p- value = 6.45 × 10−13), where stronger evidence was seen with 
AD and weaker associations with asthma and hayfever (Figure 2a, 
Table S11). Bipolar disorder was associated with the broad aller-
gic disease phenotype and appeared to be driven by asthma. This 
association was not consistent for hayfever or AD. (Figure 2a, 
Table S11). Of the allergic disease phenotypes investigated, only 
hayfever showed evidence of association with schizophrenia with 
a protective direction of effect (OR=0.41; 95% CI: 0.23– 0.70; p- 
value = 1.36×10−3) (Figure 2a, Table S11). All phenotypes showed ev-
idence of association with neuroticism, most strongly with the broad 
allergic disease phenotype, asthma and AD (Figure 2b, Table S11).
3.2  |  MR analyses
3.2.1  |  Causal effect of allergic disease genetic risk 
upon psychiatric traits— broad phenotype
Two- sample MR found little evidence that genetic liability for the 
broad allergic disease phenotype causally increases the risk of psy-
chiatric traits (Figure 2a, Table 2, S12). When investigating the causal 
effect upon MDD risk, the MR estimate was in a consistent direction 
with that found phenotypically (Figure 2a); however, the phenotypic 
association failed to replicate in the MR analysis (OR=1.01 per dou-
bling odds of allergic disease; 95% CI: 0.97– 1.06; P- value=0.51). 
These estimates suggest that a reduction in MDD risk >21% or in-
crease in risk MDD >6%, which would be clinically important ef-
fects, is unlikely. There was weak evidence that genetic liability for 
the broad allergic disease phenotype increased the risk bipolar dis-
order. The direction of effect was consistent with the phenotypic 
estimate, though the confidence interval crossed the null (OR=1.05; 
95% CI: 0.99– 1.12; P- value=0.10) (Figure 2a, Table 2, S12), suggest-
ing a reduction in risk >1% or increase >12% is unlikely. The magni-
tude of effect was also smaller than that found phenotypically.
When looking at the causal effects on anxiety, schizophrenia and 
neuroticism, the phenotypic association we observed with the broad 
allergic disease phenotype failed to replicate, and causal effect esti-
mates were null (Figure 2a,b).
3.2.2  |  Causal effect of allergic disease 
genetic risk upon psychiatric traits— 
individual phenotypes
When assessing individual allergic disease phenotypes, the strong-
est effect was found between hayfever and increased risk of bipo-
lar disorder (OR=1.09; 95% CI: 1.00– 1.19; p- value=0.06) (Table 2, 
S12, Figure S2) and effect estimates were in a consistent direction 
across sensitivity analyses. The MR- Egger model suggested a larger 
effect; however, evidence for this effect was weak (Table S12, 
Figure S3). No variants were excluded from the hayfever genetic 
instrument upon Steiger filtering. However, the confidence interval 
did cross the null and some heterogeneity was detected (Q=65; P- 
value = 3.69 × 10−04). There was little evidence of a phenotypic as-
sociation between hayfever and bipolar disorder, and effects were 
in opposing directions for self- report and diagnosis. When per-
forming a look up of the hayfever variants in PhenoScanner, there 
F I G U R E  1  Schematic representation of MR analyses. (A) Allergic 
disease SNPs were used as genetic instruments to investigate the 
causal effect of allergic disease liability upon various psychiatric 
disorders and mental health outcomes. (B) SNPs for various 
psychiatric disorders were used as genetic instrument to investigate 
to causal effect of liability for psychiatric disorders and mental 
health outcomes upon allergic disease. SNP = single nucleotide 
polymorphism
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was some evidence of an association with education (Table S14); 
however, effect estimates were small in comparison with the ef-
fect on hayfever so any effects on the MR estimates are likely to 
be negligible.
Although the strongest phenotypic association was identified 
between bipolar disorder and asthma, we found little evidence 
that genetic liability for asthma influenced the risk of bipolar dis-
order (Figure S4) and the confidence intervals did not overlap 
with the phenotypic estimates (OR = 1.04; 95% CI: 0.98– 1.10; 
p- value = 0.19).
While anxiety and neuroticism were phenotypically associated 
with asthma, AD and hayfever, there was little evidence that these 
relationships were causal in the MR analysis. The causal effect esti-
mates were close to the null and were generally not in a consistent 
direction to the phenotypic estimates (Figures S2, S4- S6).
3.2.3  |  Casual effect of psychiatric disorder genetic 
risk upon allergic disease.
We describe these results in full in the Supplementary Materials 
(Table S13, Figure S7). In brief, we found little evidence that any 
of the mental health phenotypes causally affected the broad al-
lergic disease phenotype. The strongest evidence was between 
MDD and neuroticism genetic risk on the broad allergic disease 
phenotype; however, the MDD effect estimates were of a smaller 
magnitude than the phenotypic associations and the confidence in-
tervals did not overlap, while the neuroticism effect estimate was 
in the opposing direction to the phenotypic association (Table S13, 
Figures S7- S9).
For the individual allergic disease phenotypes, the strongest 
evidence was found for bipolar disorder genetic liability having a 
protective effect upon hayfever (OR = 0.94; 95% CI: 0.90– 0.99; p- 
value = 0.02) (Table S13, Figure S10), which is a smaller magnitude 
of effect than found for hayfever genetic risk upon bipolar disorder. 
However, a protective effect of bipolar disorder upon hayfever was 
not observed in the phenotypic analysis.
4  |  DISCUSSION
We investigated the association between allergic disease and mental 
health using both observational regression based on UKB data (a UK 
longitudinal cohort aged 40 years and over), and two- sample MR ap-
proaches based on publicly available GWAS summary data. With the 
exception of schizophrenia, we found strong evidence of phenotypic 
associations between all mental health and personality phenotypes in-
vestigated with the broad allergic disease phenotype, particularly with 
F I G U R E  2  Phenotypic association and causal effects of allergic disease on mental health and personality traits. (A) Observational 
analysis: Estimates (ORs) given for odds of mental health traits in allergic disease sufferers versus non- sufferers. MR Analysis: Estimates are 
given for odds of mental health outcomes per doubling odds of broad allergic disease phenotype. (B) Observational analysis: Neuroticism 
estimate (β) given for change in summary score in allergic disease sufferers versus non- sufferers. CI, confidence interval. MR Analysis: Causal 
estimate given for change in total neuroticism score per doubling odds of broad allergic disease phenotype. CI, confidence interval
TA B L E  2  Random- effects IVW MR analyses for causal effect of 




(95% CI) p- value
Allergic disease MDD 1.01 (0.97, 
1.06)
.51
Bipolar disorder 1.05 (0.99, 
1.12)
.10
Anxiety 0.99 (0.89, 
1.11)
.90
Schizophrenia 1.06 (0.99, 
1.13)
.08
Neuroticisma 0.01 (−0.01, 
0.03)
.38
Asthma MDD 0.99 (0.96, 
1.03)
.71
Bipolar disorder 1.04 (0.98, 
1.10)
.19
Anxiety 0.98 (0.88, 
1.10)
.76
Schizophrenia 1.01 (0.95, 
1.07)
.78
Neuroticisma 0.00 (−0.02, 
0.03)
.90
Atopic dermatitis MDD 1.02 (0.97, 
1.07)
.50
Bipolar disorder 1.04 (0.96, 
1.13)
.34
Anxiety 1.06 (0.97, 
1.16)
.19
Schizophrenia 1.01 (0.93, 
1.10)
.73
Neuroticisma 0.01 (−0.02, 
0.03)
.64
Hayfever MDD 1.00 (0.94, 
1.07)
.98
Bipolar disorder 1.09 (1.00, 
1.19)
.06
Anxiety 1.00 (0.90, 
1.12)
.95






Note: Estimates given for odds of mental health outcome per doubling 
odds of allergic disease phenotype.
Abbreviations: CI, confidence interval; MDD, major depressive disorder.
aEstimates given for change in total neuroticism score per doubling 
odds of allergic disease phenotype.
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depression, replicating findings previously reported in a Taiwanese 
population.3 We also identified associations with specific allergic 
diseases (hayfever, AD, asthma). Anxiety and neuroticism were phe-
notypically associated with each of the individual diseases, but the as-
sociation between the broad allergic disease phenotype and bipolar 
disorder appeared to be driven by asthma. However, when using an 
MR approach, we found very little evidence that any of these pheno-
typic associations were likely to be causal. Where there was evidence 
for this, the causal effect estimates were of a much smaller magnitude. 
Given these results, it seems likely that most phenotypic associations 
between allergic disease and mental health are due to confounding or 
some other form of bias. This suggests that the observed clinical co-
morbidity between allergic disease and mental health problems is un-
likely to be causal. Therefore, intervening to prevent onset of allergic 
disease is unlikely to directly improve mental health (and vice versa).
We did find some evidence of a causal effect of genetic liability 
for bipolar disorder upon hayfever risk. However, we did not find ev-
idence for a phenotypic association. Although evidence for a casual 
effect of hayfever genetic risk upon bipolar disorder was weak, it 
is possible that this relationship acts through inflammatory mecha-
nisms. This would support the inflammatory hypothesis, where sev-
eral psychiatric traits, including bipolar disorder, have been reported 
to be associated with increased inflammatory markers.11
Although our findings suggest there is no direct causal effect 
of onset of allergic disease on the onset of mental health pheno-
types, there is some evidence that effectively treating skin disease 
can improve mental well- being.41,42 A recent report by the All- Party 
Parliamentary Group on Skin has recommended that patients with 
a chronic skin condition should receive an annual assessment of the 
psychological impact of their condition.43 In our study, the genetic 
instruments we used were identified in GWAS which looked at the 
onset of allergic disease or mental health phenotypes. In primary 
care and trial settings, interventions often aim to improve these phe-
notypes rather than prevent their onset, which could have different 
causal relationships.13 Methods are currently being developed which 
will enable us to investigate the causal effects of disease progression 
rather than disease onset, such as the recent slope hunter approach 
proposed by Mahmood and colleagues.44 Future work should follow 
up these relationships to investigate whether interventions that aim 
to improve allergic disease show stronger evidence of a causal effect 
on mental health (and vice versa).
Triangulating findings using both observational and MR ap-
proaches using studies with large sample sizes, and across multiple 
contexts by comparison with published findings from international 
cohorts, is a particular strength of this study. This enables us to com-
pare the magnitude of effect across approaches. For the majority 
of our analyses, the confidence intervals for the observational and 
causal effect estimates did not overlap, indicating that any causal 
effect of allergic disease is likely to be much smaller than the pheno-
typic estimates suggest. Although we did not find strong evidence 
for a clinically relevant causal effect of allergic disease on mental 
health (or vice versa), the MR estimates particularly for the allergic 
disease exposures are precise, enabling us to estimate the maximum 
causal effect we are likely to see. In addition, investigating both the 
broad allergic disease phenotype and separating out the specific ef-
fects of asthma/AD/hay fever enabled us to determine whether the 
relationship is driven by certain phenotypes.
There are some limitations to this study that should be consid-
ered. First, the available genetic instruments for the mental health 
phenotypes were weaker than those used for the allergic disease 
phenotypes (as indicated by R2 and mF values in Table S10). It is 
therefore difficult to rule out bidirectional effects that were not 
uncovered, as it is possible that we did not have enough power to 
detect causal effects of mental health and personality on allergic 
disease. Second, although the evidence was strongest for the causal 
effect of bipolar disorder genetic liability upon hayfever, after ac-
counting for multiple testing using a Bonferroni correction, none of 
the MR analyses passed the suggested threshold (p < 1.25 × 10−3). 
However, this approach is likely overly conservative given the cor-
relation between our phenotypes. Third, the UKB phenotypes used 
within this study were predominantly self- reported, which could 
increase the potential for misreporting. However, where possible 
we repeated the observational analysis using a stricter definition of 
major depression and bipolar disorder, and the results were consis-
tent. Fourth, there was some sample overlap in our MR analyses of 
neuroticism and both the broad allergic disease and hayfever pheno-
type, due to the inclusion of UKB in both GWAS. Sample overlap can 
bias the causal estimate towards the phenotypic exposure- outcome 
association31; however, our MR estimates for these associations 
were null so this was not an issue. Fifth, the results from this study 
may not be generalizable across populations. Both the observational 
data and the publicly available GWAS data used for the MR used 
data from predominantly white European samples in adulthood. 
More diverse GWAS are required to improve transferability of re-
sults across populations and age groups.45 Our phenotypic analyses 
were also performed in a cohort of UK adults recruited when they 
were in their fourth decade or above, this may limit the generalizabil-
ity of our findings surrounding disorders that are more prevalent in 
childhood and adolescence. This is reflected in the lower prevalence 
rates of allergic disease in our sample compared with the UK popu-
lation. It is also possible that since cases of allergic disease were self- 
reported at recruitment, these may reflect more severe phenotypes 
and/or disease present in UKB adult participants. While our pheno-
typic analysis is restricted to adults aged 40 years and over, the MR 
analyses reflect the effect of allergic disease across the life course 
rather than during a specific developmental period, any effects spe-
cific to childhood may therefore be diluted in this sample. Finally, it 
is important to note that for binary phenotypes MR estimates the 
effect of genetic liability to a phenotype, not the effect of actually 
having the phenotype or disease.30 It is therefore possible the effect 
of experiencing a specific allergic disease or mental health disorder 
could have different effects to those reported here.
In conclusion, few of the observed associations between allergic 
disease and mental health were replicated. The causal effect we did 
identify appears to be much lower in magnitude than that suggested 
observationally. This suggests that the majority of co- incidence 
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observed clinically is unlikely to be causal. Therefore, intervening to 
prevent onset of allergic disease is unlikely to directly prevent the 
onset of mental ill- health. But future work should aim to investigate 
whether interventions that aim to improve allergic disease have a 
causal effect on mental health (and vice versa).
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